Results 81 to 90 of about 20,482 (116)

A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults. [PDF]

J Endocr Soc
Laffel LM, Danne T, Klingensmith GJ, Schueler E, Tartakovsky I, Nessralla L, Zeitler P, Willi S.   +7 more
europepmc   +1 more source

AI/ML-Driven DPP-4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps. [PDF]

Arch Pharm (Weinheim)
Manhas A, Dutta R, Piotto S, Amin SA.
europepmc   +1 more source

Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption. [PDF]

Biomed Res Int, 2020
Qi J, Kitaura H, Shen WR, Ogawa S, Ohori F, Noguchi T, Marahleh A, Nara Y, Adya P, Mizoguchi I.   +9 more
europepmc   +1 more source

Assessment of Knowledge and General Attitudes of Primary Care Physicians Toward Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Drugs in the Management of Type 2 Diabetes Mellitus in the Qassim Region. [PDF]

Cureus
Aljulajil F, Rabbani U.
europepmc   +1 more source

Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. [PDF]

Diabetes Obes Metab
Kaku K, Shimoda M, Osonoi T, Iwamoto M, Kaneto H.   +4 more
europepmc   +1 more source

Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats. [PDF]

Drug Des Devel Ther
Chayah M, Luque-González A, Gómez-Pérez V, Salagre D, Al-Shdaifat A, Campos JM, Conejo-García A, Agil A.   +7 more
europepmc   +1 more source

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study. [PDF]

Diabetes Metab Syndr Obes
Itsukaichi A, Yoshikawa F, Fuchigami A, Iwata Y, Sato G, Miyagi M, Hirose T, Uchino H.   +7 more
europepmc   +1 more source

DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient. [PDF]

Intern Med, 2020
Usami J, Takezawa Y.
europepmc   +1 more source

DPP-4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. [PDF]

Physiol Rep
Harris DD, Sabe SA, Broadwin M, Bellam K, Xu CM, Li JW, Abid MR, Sellke FW.   +7 more
europepmc   +1 more source

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. [PDF]

Transl Clin Pharmacol, 2020
Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE.   +5 more
europepmc   +1 more source